PreprintCC BY-NCbioRxiv
One-Dose Efficacy of Long-Acting Sorfequiline in a Mouse Model of Tuberculosis Preventive Therapy
- 1Johns Hopkins University School of Medicine
Abstract
Rationale: Tuberculosis preventive therapy (TPT) is essential for global tuberculosis control, yet estimated coverage remains well below global targets. Current World Health Organization (WHO)-recommended regimens require 1-9 months of treatment and are associated with suboptimal completion rates. Long-acting injectable (LAI) formulations offer the potential to improve TPT uptake and completion, with ideal products providing "one-and-done" options via a single administration. Sorfequiline, a second-generation diarylquinoline with superior potency over bedaquiline and lower QT prolongation risk, is a promising candidate for LAI TPT.
Related
- Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above – Lessons from a tuberculosis preventive therapy surge activity in Zambia
- Factors influencing tuberculosis preventive treatment implementation in India: A hybrid inductive-abductive thematic analysis using implementation framework
- Predicted choice and acceptability of regimens for tuberculosis preventive treatment among people living with HIV in Uganda – A discrete choice experiment
- Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal ® ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)
- A Computational Re-evaluation of Spatial Trials for Zoonotic Tuberculosis Control: Model Misspecification, Diagnostic Miss-classification, and the Illusion of Wildlife Culling Efficacy
BibTeX
@misc{li2026onedose,
title = {{One-Dose Efficacy of Long-Acting Sorfequiline in a Mouse Model of Tuberculosis Preventive Therapy}},
author = {S.-Y. Li and J. J. Hobson and N. C. Ammerman and H. Pertinez and J. Sharp and N. Fotouhi and S. Rannard and A. Owen and E. L. Nuermberger},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.22.752266},
url = {https://www.biorxiv.org/content/10.64898/2026.09.22.752266v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - One-Dose Efficacy of Long-Acting Sorfequiline in a Mouse Model of Tuberculosis Preventive Therapy
AU - S.-Y. Li
AU - J. J. Hobson
AU - N. C. Ammerman
AU - H. Pertinez
AU - J. Sharp
AU - N. Fotouhi
AU - S. Rannard
AU - A. Owen
AU - E. L. Nuermberger
PY - 2026
DA - 2026/09/22
PB - bioRxiv
DO - 10.64898/2026.09.22.752266
UR - https://www.biorxiv.org/content/10.64898/2026.09.22.752266v1
AB - Rationale: Tuberculosis preventive therapy (TPT) is essential for global tuberculosis control, yet estimated coverage remains well below global targets. Current World Health Organization (WHO)-recommended regimens require 1-9 months of treatment and are associated with suboptimal completion rates. Long-acting injectable (LAI) formulations offer the potential to improve TPT uptake and completion, with ideal products providing "one-and-done" options via a single administration. Sorfequiline, a second-generation diarylquinoline with superior potency over bedaquiline and lower QT prolongation risk, is a promising candidate for LAI TPT.
ER -